Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Lymphoblastic LymphomaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT06533748
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
- Conditions
- NeuroblastomaChildhood NeuroblastomaHigh-risk Neuroblastoma
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06528496
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Target Recruit Count
- 528
- Registration Number
- NCT06516978
Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma
- Conditions
- FL
- Interventions
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Target Recruit Count
- 30
- Registration Number
- NCT06474481
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
- Conditions
- Lymphoma, Follicular
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 90
- Registration Number
- NCT06425302
- Locations
- 🇺🇸
Local Institution - 0020, New Brunswick, New Jersey, United States
🇺🇸Local Institution - 0036, New York, New York, United States
🇺🇸Utah Cancer Specialists, Salt Lake City, Utah, United States
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
- Conditions
- Stage I Kidney Wilms TumorStage II Kidney Wilms TumorStage III Kidney Wilms TumorStage IV Kidney Wilms Tumor
- Interventions
- Procedure: Computed TomographyProcedure: NephrectomyProcedure: Bone ScanOther: Patient ObservationProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Ultrasound ImagingProcedure: X-Ray Imaging
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1656
- Registration Number
- NCT06401330
- Locations
- 🇺🇸
East Carolina University, Greenville, North Carolina, United States
🇺🇸Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States
🇺🇸Albany Medical Center, Albany, New York, United States
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Conditions
- T-cell LymphomaT-cell Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06390319
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-03-05
- Target Recruit Count
- 53
- Registration Number
- NCT06387121
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
- Conditions
- Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 850
- Registration Number
- NCT06356129
- Locations
- 🇺🇸
USA Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
Ma-Spore ALL 2020 Study
- Conditions
- B Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT06336395
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Kuala Lumpur, Malaysia
🇸🇬KK Women's and Children's Hospital, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.